Beximco Pharma Requests Extension to Publish Q3 Results
The pharmaceutical company has requested an extension to publish its Q3 financial results due to an ongoing legal matter regarding the appointment of additional independent directors.
The pharmaceutical company has requested an extension to publish its Q3 financial results due to an ongoing legal matter regarding the appointment of additional independent directors.
The pharmaceutical company denies allegations of corruption in Covid-19 vaccine procurement and provides an update on a regulatory order regarding its board of directors.
The pharmaceutical company faces regulatory uncertainty over the proposed appointment of additional independent directors to its board, with a court decision expected by mid-March.
The pharmaceutical company has announced a change in its Board of Directors, with a new Non-Executive Director nominated by a major shareholder.
The generic drug manufacturer reported an 8.8% increase in net sales and a 17.5% rise in profit after tax for the half-year. Export sales surged by 31.6%, with expansion into new markets.
Pharmaceutical company faces potential Board shake-up as regulator seeks to appoint new directors
The pharmaceutical company held its Annual General Meeting, approving a 40% cash dividend and a name change, but the announcement contains no major updates.
Pharmaceutical company Beximco announces upcoming AGM and routine corporate updates.
Pharmaceutical company reports modest Q1 revenue growth, but remains confident in its business strategy.
The pharmaceutical manufacturer has won its appeal against an interim court order, leading to the lifting of a temporary trading suspension on its shares.